查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2015152

神经血管和神经系统医疗设备市场：按产品、适应症、技术、最终用户和分销管道划分－2026-2032年全球市场预测

Neurovascular Neurology Devices Market by Product, Indication, Technology, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年神经血管和神经医疗设备市场价值为45.8亿美元，预计到2026年将成长至47.8亿美元，复合年增长率为5.46%，到2032年将达到66.5亿美元。

主要市场统计数据
基准年 2025 45.8亿美元
预计年份：2026年 47.8亿美元
预测年份 2032 66.5亿美元
复合年增长率 (%) 5.46%

策略性地引入神经血管医疗设备，重点关注临床紧迫性、多学科护理路径以及影响治疗结果的技术趋势。

神经血管器材领域正处于技术创新、临床紧迫性和不断发展的诊疗路径的交汇点，因此需要为医疗保健、投资和监管领域的相关人员提供清晰、以临床为导向的介绍。本文概述了当前形势，重点介绍了微创治疗和影像技术的进步如何改变了急性中风治疗、动脉瘤管理和血管畸形治疗。临床医生越来越依赖兼具精密机械性能和更佳输送能力的精准器械，而影像解析度和手术引导系统的同步改进也推动了这一趋势。

设备工程、影像分析和医疗保健服务系统的重新设计如何改变神经血管治疗的临床部署、采购和创新途径。

神经血管介入治疗的现状正经历着一场变革，这主要得益于器材工程、数位诊断和医疗系统组织等方面的整合发展。在器材层面，纯粹的机械解决方案正加速整合式平台转型。新型血流渗透性结构和生物活性表面处理技术体现了在最大限度减少辅助手术的同时，实现动脉瘤持续闭塞的理念；而取栓器和抽吸装置设计的创新则优先考虑血栓的安全捕获和减少内皮损伤。同时，影像和分析技术的进步使得病变表征和手术规划更加精准，加速了针对特定解剖和病理亚型的器械的研发。

评估美国新关税对整个医疗设备产品组合的采购、製造地转移和创新资金筹措的累积营运和策略影响。

美国将于2025年开始加征关税，这将为参与全球神经血管器械生产和分销的相关人员带来新的挑战，其累积影响将波及采购、製造以及研发投资决策。关税带来的成本压力在跨境供应链中集中的零件和原材料上最为显着，例如特殊合金、导管轴和渗透性标记。随着这些投入成本的上升，製造商被迫做出策略性选择：自行承担成本、重新分配利润，或将价格上涨转嫁给经销商和医疗系统。

将产品设计、临床应用、交付技术、医疗保健环境和分销策略联繫起来的细分市场洞察，以推动产品采用和差异化。

精细的細項分析揭示了临床需求、器材机制和分销管道动态如何相互作用，从而影响产品上市模式和商业性优先事项。在产品类型中，球囊血管成形术导管依其球囊技术可分为顺应性球囊和非顺应性球囊。顺应性球囊适用于细部的血管重塑，而非顺应性球囊则适用于需要精确扩张管腔的情况。栓塞弹簧圈分为裸弹簧圈、涂层弹簧圈和水凝胶弹簧圈，每种亚型在即时闭塞、组织整合和长期稳定性之间各有优劣，影响临床医生的选择。血流导向装置分为可生物降解型和永久性型。可生物降解型血流导向装置更受那些希望在不承受终身植入负担的情况下进行血管修復的临床医生青睐，而永久性血流导向装置仍然是某些复杂动脉瘤形态的标准选择。神经血管支架采用球囊扩张型或自扩张式结构，选择取决于所需的径向支撑力、血管曲率和输送限制。血栓摘取支架，其特点在于血栓捕获机制、输送能力以及与抽吸辅助装置的兼容性。

美洲、欧洲、中东和非洲以及亚太地区的临床基础设施的区域趋势和差异影响着监管路径、报销重点和部署模式。

区域趋势反映了监管、医疗服务体系和支付方行为的差异，这些差异影响神经血管器械领域的临床实践和商业策略。在美洲，完善的卒中治疗体系和一体化的医院网络促进了先进血栓切除术和血流导向技术的快速应用。此外，高水准的医疗中心和大量的手术量使得强化训练计画得以开展，从而有助于收集真实世界的临床证据，并进一步加速器械的推广应用。区域采购环境通常强调证明综合治疗的经济效益和价值，促使器械供应商将临床数据与健康经济学论点结合。

透过运用竞争定位和伙伴关係策略，我们将临床证据、训练计画和供应链韧性结合，以确保在介入医师中保持持续的偏好。

神经血管器材领域的竞争动态取决于规模优势与敏捷创新之间的平衡。大型医疗设备公司利用其广泛的临床试验网络、丰富的监管合规经验和一体化的服务交付体系，与患者数量庞大的医疗机构保持长期合作关係。这些成熟企业通常会投资于互补技术、培训机构和长期的上市后监测，以巩固临床认可并向支付方证明其价值。同时，敏捷的新兴企业正在推动差异化技术的研发，例如突破性的生物可吸收血流导引装置、先进的聚合物涂层线圈和新一代吸痰导管。这些技术一旦拥有令人信服的临床数据支持，就能迅速赢得临床关注。

为领导者提供一系列切实可行的建议，以协调临床证据、供应链韧性、商业化模式和支付方参与，从而实现永续成长。

产业领导者应采取多管齐下的策略，将产品创新与严格的商业化、与临床机构的合作以及供应链韧性相结合。首先，他们应优先考虑以患者为中心的临床项目，这些项目能够产生有意义的终点指标和可操作的证据，从而引起临床医生和支付方的共鸣。註册研究和可操作的临床试验是随机试验的补充，有助于更快地获得更具普遍适用性的见解。其次，他们应重新设计供应链策略，透过认证替代供应商、探索关键零件的近岸外包以及建立库存缓衝来降低关税和零件集中度风险，从而确保产品按计划上市。

检验临床和商业性发现，该研究结合了对临床医生、专家小组的访谈和系统的文献整合。

本调查方法结合了严谨的一手资料和二手资料研究，以确保研究结果对相关人员具有相关性、实用性和意义。一手资料研究包括对介入医师、医院采购经理和医疗设备公司高阶主管进行结构化访谈，以了解他们对器械选择、手术偏好和推广障碍的实际观点。除访谈外，还组织了由中风和血管神经外科专家组成的专题研讨会，以检验临床假设并解读手术趋势。二手资料研究系统地回顾了同行评审文章、临床试验註册资料、监管申报文件和医疗设备技术文献，以交叉检验研究结果并阐明创新发展轨迹。

简明扼要的总结强调，需要协调创新、证据产生和商业性实施，才能将医疗设备的进步与改善病患预后连结起来。

总之，神经血管和神经系统领域的医疗设备市场呈现出快速的技术进步、不断演变的医疗服务模式以及对价值链中价值和韧性的日益重视等特征。儘管医疗设备设计和影像技术的进步显着提升了手术能力，但可靠的临床证据、合理的报销策略以及贯穿整个医疗体系的完善营运框架对于永续应用至关重要。政策变化和贸易趋势带来了新的限制因素，因此需要透过采购多元化和策略伙伴关係等积极主动的风险缓解措施来应对。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：神经血管与神经系统医疗设备市场：依产品划分

  • 球囊血管成形术导管
    • 符合规范的气球
    • 不合规的气球
  • 栓塞线圈
    • 裸露线圈
    • 涂层线圈
    • 水凝胶线圈
  • 分流器
    • 可生物降解的导流板
    • 永久性分流器
  • 神经血管支架
    • 球囊扩张型支架
    • 自动扩张型支架
  • 血栓摘取支架系统
    • 单人纸牌
    • 特雷沃

第九章：神经血管与神经系统医疗设备市场：依适应症划分

  • 动脉瘤闭塞
    • 梭形动脉瘤
    • 囊状动脉瘤
  • 动静脉畸形
  • 出血性中风
  • 缺血性中风
    • 循环系统前中风
    • 循环后中风

第十章：神经血管与神经系统医疗设备市场：依技术划分

  • 化学溶栓疗法
  • 血液旁路
  • 机械血栓切除术
    • 吸痰管
    • 血栓摘取支架

第十一章：神经血管与神经系统医疗设备市场：依最终用户划分

  • 门诊手术中心
  • 医院
  • 专科诊所

第十二章：神经血管与神经系统医疗设备市场：依分销管道划分

  • 直销
  • 销售代理

第十三章：神经血管与神经系统医疗设备市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：神经血管与神经系统医疗设备市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：神经血管和神经系统医疗设备市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国神经血管与神经医疗设备市场

第十七章：中国神经血管与神经医疗设备市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Acandis GmbH
  • Asahi Intecc Co., Ltd.
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Cerenovus, LLC
  • Johnson & Johnson
  • Medtronic plc
  • MicroPort Scientific Corporation
  • MicroVention, Inc.
  • Penumbra, Inc.
  • Stryker Corporation
  • Terumo Corporation
Product Code: MRR-036C5CF3B4E4

The Neurovascular Neurology Devices Market was valued at USD 4.58 billion in 2025 and is projected to grow to USD 4.78 billion in 2026, with a CAGR of 5.46%, reaching USD 6.65 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.58 billion
Estimated Year [2026] USD 4.78 billion
Forecast Year [2032] USD 6.65 billion
CAGR (%) 5.46%

A strategic introduction to neurovascular devices emphasizing clinical urgency, multidisciplinary care pathways, and technological trends shaping procedural outcomes

Neurovascular neurology devices are at the intersection of technological innovation, clinical urgency, and evolving care pathways, demanding a clear, clinically informed introduction for stakeholders across healthcare, investment, and regulatory spheres. This introduction frames the current landscape by highlighting how advances in minimally invasive therapies and imaging have reshaped acute stroke care, aneurysm management, and the treatment of vascular malformations. Clinicians increasingly rely on precision devices that integrate refined mechanical properties with improved deliverability, and this trend is supported by parallel enhancements in imaging resolution and procedural guidance systems.

The clinical context is defined by persistently high morbidity and mortality associated with cerebrovascular events, which creates sustained pressure to improve time-to-treatment, procedural success rates, and long-term neurological outcomes. In response, device developers have focused on reliability of deployment, reduced intraprocedural complications, and materials science innovations that modulate thrombogenicity and healing responses. At the same time, health systems are realigning care networks to prioritize rapid triage, centralized thrombectomy-capable centers, and expanded roles for ambulatory procedural settings where appropriate.

Regulatory and reimbursement dynamics remain central to adoption trajectories, with approvals increasingly tied to robust clinical endpoints and post-market surveillance commitments. Collaboration among interventional neuroradiologists, neurosurgeons, and stroke neurologists is deepening, and this multidisciplinary engagement is accelerating iterative device improvements and real-world evidence generation. Taken together, these forces situate neurovascular devices as a strategic priority for organizations seeking durable impact on patient outcomes and long-term value creation.

How device engineering, imaging analytics, and care delivery redesign are together reshaping clinical adoption, procurement, and innovation pathways in neurovascular care

The landscape of neurovascular interventions is undergoing transformative shifts driven by convergent advances in device engineering, digital diagnostics, and health-system organization. At the device level, a move from purely mechanical solutions toward integrated platforms has accelerated: newer flow diversion constructs and bioactive surface treatments reflect an emphasis on durable aneurysm occlusion with fewer adjunctive procedures, while innovations in retriever and aspiration designs prioritize clot engagement and reduced endothelial trauma. Concurrently, imaging and analytics enhancements are enabling more accurate lesion characterization and procedural planning, which in turn supports device iteration that targets specific anatomical and pathological subtypes.

Operationally, there is an unmistakable shift toward decentralizing certain procedures to low-acuity settings where patient selection and streamlined protocols permit safe, cost-efficient interventions. This hybridization of care delivery models is being enabled by device designs optimized for outpatient use and simplified inventory management. In addition, clinical trial designs are evolving to emphasize adaptive protocols and real-world evidence, allowing faster translation of promising technologies while preserving methodological rigor.

On the macro front, supply chain resilience and regulatory harmonization are influencing product roadmaps and market entry strategies. Companies are investing in localized manufacturing, strategic partnerships, and value-based contracting to navigate reimbursement pressures and procurement rationalization. Taken together, these transformative shifts are not incremental; they reshape competitive positioning, clinician decision-making, and the timelines for broad clinical adoption.

Evaluating the cumulative operational and strategic consequences of new U.S. tariffs on procurement, manufacturing relocation, and innovation funding across device portfolios

The imposition of United States tariffs in 2025 has introduced a new layer of complexity for stakeholders engaged in the global production and distribution of neurovascular devices, with cumulative effects that extend across procurement, manufacturing, and R&D investment decisions. Tariff-driven cost pressure is most immediately apparent in components and raw materials that are concentrated in cross-border supply chains, including specialty alloys, catheter shafts, and radio-opaque markers. When these inputs become more expensive, manufacturers face strategic choices about absorbing costs, reallocating margins, or passing increases downstream to distributors and health systems.

Consequently, procurement organizations and hospital systems are reassessing supplier diversification and contract terms, accelerating efforts to secure price predictability through longer-term agreements or local sourcing arrangements. For device companies, the tariffs incentivize supply chain reconfiguration: nearshoring production, qualifying alternate suppliers, and increasing vertical integration where feasible. These responses can mitigate exposure over time but often require upfront capital and extended qualification timelines that compete with R&D allocations.

Smaller innovators are particularly vulnerable, as elevated import costs may constrain their ability to scale clinical trials and commercial launches without strategic partnerships. At the same time, larger incumbents with diversified manufacturing footprints can leverage scale to normalize pricing changes, albeit at the cost of redirecting resources that might otherwise fund product development or market expansion. In aggregate, the tariffs catalyze a re-evaluation of the cost-to-serve for international product portfolios, reinforcing the importance of resilience planning, scenario modeling, and proactive dialogue with payers to preserve access for clinicians and patients.

Segment-level insights connecting product design, clinical indications, delivery technologies, care settings, and distribution strategies to drive adoption and differentiation

A nuanced segmentation analysis reveals how clinical need, device mechanics, and channel dynamics interact to shape adoption patterns and commercial priorities. Within product categories, balloon angioplasty catheters are differentiated by compliant versus noncompliant balloon technologies, where compliant balloons are preferred for delicate vessel remodeling and noncompliant variants are favored when precise luminal expansion is required. Embolic coils vary across bare coils, coated coils, and hydrogel coils, and each subtype presents trade-offs between immediate occlusion, tissue integration, and long-term stability that inform clinician selection. Flow diverters divide into biodegradable and permanent devices; biodegradable flow diverters appeal to clinicians seeking vessel restoration without lifelong implant burden, while permanent flow diverters remain the default for certain complex aneurysm morphologies. Neurovascular stents are produced as balloon-expandable or self-expanding constructs, with choice contingent on radial force needs, vessel tortuosity, and delivery constraints. Stent retriever systems, exemplified by Solitaire and Trevo designs, are distinguished by clot engagement mechanics, deliverability profiles, and compatibility with aspiration adjuncts.

When analyzed by indication, aneurysm occlusion strategies must account for fusiform versus saccular anatomy, with device selection influenced by neck morphology and parent vessel involvement. Treatments for arteriovenous malformations require a different procedural mindset focused on nidus access and embolic control, while hemorrhagic stroke interventions prioritize hemostatic stabilization and prevention of rebleeding. Ischemic stroke management bifurcates into anterior circulation and posterior circulation strokes, where anatomical access, collateral circulation, and time sensitivity dictate device choice and procedural strategy.

Technological segmentation highlights distinctions between chemical thrombolysis, flow diversion, and mechanical thrombectomy. Mechanical thrombectomy further subdivides into aspiration catheter strategies and stent retrievers, each offering complementary strengths in clot retrieval efficiency and compatibility with adjunctive devices. End user segmentation shows divergent needs among ambulatory surgical centers, hospitals, and specialty clinics: ambulatory settings require devices optimized for streamlined turnover and lower complexity cases, hospitals maintain broad inventories for high-acuity procedures, and specialty clinics emphasize devices that support repeatable interventions and specialized follow-up care. Distribution channel dynamics between direct sales and distributors influence training, service levels, and pricing transparency, with direct sales enabling tighter clinical support and distributors offering broader geographic reach and inventory buffering. Collectively, these segmentation lenses illuminate how product design, clinical indication, technology choice, care setting, and channel strategy must be aligned to realize both clinical impact and commercial success.

Regional dynamics and clinical infrastructure differences that influence regulatory pathways, reimbursement priorities, and adoption models across Americas, EMEA, and Asia-Pacific

Regional dynamics shape both clinical practice and commercial strategy across the neurovascular device landscape, reflecting differences in regulation, provider infrastructure, and payer behavior. In the Americas, robust stroke systems of care and consolidated hospital networks support rapid adoption of advanced thrombectomy and flow diversion technologies; centers of excellence and high procedural volumes enable intensive training programs and foster real-world evidence collection that further accelerates device uptake. The purchasing environment in this region often emphasizes bundled care economics and value demonstration, prompting device sponsors to couple clinical data with health-economic narratives.

Europe, the Middle East & Africa exhibits heterogeneity driven by national regulatory pathways, variable reimbursement policies, and disparate access to interventionists. In Western Europe, centralized health technology assessment processes and strong clinical registries create a pathway for adoption that prioritizes long-term outcomes and cost-effectiveness. In parts of the Middle East and Africa, investment in neurointerventional capacity is emerging, but adoption is constrained by workforce distribution and infrastructure gaps, leading to targeted opportunities for scalable training and service models.

Asia-Pacific presents a large and diverse opportunity set characterized by rapid hospital expansion, increased investment in tertiary stroke centers, and local manufacturing growth. Regulatory timelines vary significantly across jurisdictions, and market entry strategies often require partnerships with regional distributors or local manufacturers. Furthermore, demographic trends and growing awareness of stroke risk factors are driving demand for both acute intervention devices and chronic management solutions, while price sensitivity in certain markets compels tailored product portfolios and flexible commercial arrangements. Across all regions, harmonizing clinical evidence generation and post-market surveillance practices remains critical to sustaining adoption and informing iterative device improvements.

Competitive positioning and partnership strategies that combine clinical evidence, training programs, and supply chain resilience to secure lasting preference among interventionists

Competitive dynamics across the neurovascular devices arena are defined by a balance between scale-driven capabilities and nimble innovation. Leading medtech firms leverage extensive clinical trial networks, broad regulatory experience, and integrated service offerings to maintain durable relationships with high-volume centers. These incumbents often invest in complementary technologies, training academies, and long-term post-market studies to entrench clinical preference and demonstrate value to payers. At the same time, agile emerging companies are advancing differentiated technologies-such as novel bioresorbable flow diverters, advanced polymer-coated coils, and next-generation aspiration catheters-that can rapidly capture clinical interest when supported by compelling procedural data.

Partnerships and strategic alliances are increasingly common, enabling smaller innovators to access commercialization expertise and scale while allowing larger firms to augment their pipelines with targeted capabilities. Mergers and acquisitions continue to be a key mechanism for acquiring novel intellectual property and expanding geographic reach, although transactions are subject to careful scrutiny given regulatory complexity and the need to integrate clinical education efforts.

Service and training models are also a point of differentiation; companies that provide hands-on proctoring, hybrid simulation programs, and post-procedural analytics strengthen clinician adoption and reduce the learning curve for complex devices. Finally, companies that proactively address supply chain resilience, cost transparency, and value demonstration position themselves favorably with health systems navigating budgetary and procurement constraints. Collectively, these strategic behaviors define a competitive environment where clinical evidence, support infrastructure, and supply-chain reliability are as consequential as device performance.

A pragmatic set of high-impact recommendations for leaders to align clinical evidence, supply chain resilience, commercialization models, and payer engagement for durable growth

Industry leaders should adopt a multi-pronged strategy that aligns product innovation with commercialization rigor, clinical engagement, and supply chain resilience. First, prioritize clinical programs that generate meaningful, patient-centric endpoints and pragmatic evidence that resonates with clinicians and payers; registries and pragmatic trials can complement randomized studies and facilitate faster, generalizable insights. Second, redesign supply chain strategies to mitigate tariff exposure and component concentration risks by qualifying alternate suppliers, considering nearshoring for critical components, and establishing inventory buffers that preserve launch timelines.

Third, tailor commercial models to regional contexts by combining direct sales in high-volume centers with distributor partnerships in markets where breadth of coverage and local relationships are paramount. Fourth, invest in clinician training infrastructures that include simulation, proctoring, and digital decision support to shorten adoption curves and reduce procedural variability. Fifth, engage payers early with comprehensive value dossiers that articulate both clinical outcomes and health economic impact; performance-based contracting and outcome guarantees can be considered where alignment is feasible.

Finally, embed digital tools that enhance procedural planning, follow-up, and device performance monitoring to create a differentiated service layer that supports premium positioning. By executing on these interconnected priorities, industry leaders can accelerate safe adoption, manage cost pressures, and sustain investment in next-generation technologies.

A transparent mixed-methods research approach combining clinician interviews, expert panels, and systematic literature synthesis to validate clinical and commercial insights

The underlying research methodology combines rigorous primary and secondary approaches to ensure validity, relevance, and practical utility for stakeholders. Primary research included structured interviews with interventionalists, hospital procurement leaders, and device executives to capture frontline perspectives on device selection, procedural preferences, and adoption barriers. These interviews were complemented by expert panel discussions with clinicians specializing in stroke and vascular neurosurgery to validate clinical assumptions and interpret procedural trends. Secondary research involved systematic review of peer-reviewed publications, clinical trial registries, regulatory filings, and technical device literature to triangulate findings and contextualize innovation trajectories.

Data synthesis relied on cross-validation of qualitative insights with objective indicators such as device approval histories, guideline updates, and published procedural outcomes. Where appropriate, scenario analysis was applied to assess sensitivity to policy changes and supply chain disruptions. Quality control processes included independent editorial review, clinical advisor validation, and methodological documentation that outlines inclusion criteria, interview protocols, and limitations. Transparency about assumptions and the sources of evidence underpins the confidence in the insights presented, while acknowledging that clinical practice and policy environments continue to evolve and warrant ongoing monitoring.

A concise synthesis emphasizing the imperative to align innovation, evidence generation, and commercial execution to translate device advances into improved patient outcomes

In conclusion, the neurovascular neurology device environment is characterized by rapid technological progress, evolving care delivery models, and intensified attention to value and resilience in supply chains. Advances in device design and imaging have materially improved procedural capabilities, but sustainable adoption depends on robust clinical evidence, sensible reimbursement strategies, and operational readiness across healthcare systems. Policy shifts and trade dynamics have introduced new constraints that require proactive mitigation through diversified sourcing and strategic partnerships.

Future success will favor organizations that integrate clinical innovation with disciplined commercialization, invest in clinician training and post-market evidence, and adopt flexible regional strategies that respect regulatory and payer heterogeneity. By aligning product development with demonstrable outcomes and service-oriented propositions, stakeholders can better navigate the complex interplay of clinical need, economic pressures, and technological opportunity that defines this market. Continued attention to real-world performance data and collaborative engagement with the clinician community will be crucial to translating device innovation into improved patient outcomes at scale.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neurovascular Neurology Devices Market, by Product

  • 8.1. Balloon Angioplasty Catheters
    • 8.1.1. Compliant Balloons
    • 8.1.2. Noncompliant Balloons
  • 8.2. Embolic Coils
    • 8.2.1. Bare Coils
    • 8.2.2. Coated Coils
    • 8.2.3. Hydrogel Coils
  • 8.3. Flow Diverters
    • 8.3.1. Biodegradable Flow Diverters
    • 8.3.2. Permanent Flow Diverters
  • 8.4. Neurovascular Stents
    • 8.4.1. Balloon-Expandable Stents
    • 8.4.2. Self-Expanding Stents
  • 8.5. Stent Retriever Systems
    • 8.5.1. Solitaire
    • 8.5.2. Trevo

9. Neurovascular Neurology Devices Market, by Indication

  • 9.1. Aneurysm Occlusion
    • 9.1.1. Fusiform Aneurysm
    • 9.1.2. Saccular Aneurysm
  • 9.2. Arteriovenous Malformations
  • 9.3. Hemorrhagic Stroke
  • 9.4. Ischemic Stroke
    • 9.4.1. Anterior Circulation Stroke
    • 9.4.2. Posterior Circulation Stroke

10. Neurovascular Neurology Devices Market, by Technology

  • 10.1. Chemical Thrombolysis
  • 10.2. Flow Diversion
  • 10.3. Mechanical Thrombectomy
    • 10.3.1. Aspiration Catheters
    • 10.3.2. Stent Retrievers

11. Neurovascular Neurology Devices Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Neurovascular Neurology Devices Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Distributors

13. Neurovascular Neurology Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Neurovascular Neurology Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Neurovascular Neurology Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Neurovascular Neurology Devices Market

17. China Neurovascular Neurology Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Acandis GmbH
  • 18.6. Asahi Intecc Co., Ltd.
  • 18.7. Becton, Dickinson and Company
  • 18.8. Boston Scientific Corporation
  • 18.9. Cerenovus, LLC
  • 18.10. Johnson & Johnson
  • 18.11. Medtronic plc
  • 18.12. MicroPort Scientific Corporation
  • 18.13. MicroVention, Inc.
  • 18.14. Penumbra, Inc.
  • 18.15. Stryker Corporation
  • 18.16. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COMPLIANT BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COMPLIANT BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COMPLIANT BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NONCOMPLIANT BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NONCOMPLIANT BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NONCOMPLIANT BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BARE COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BARE COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BARE COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COATED COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COATED COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COATED COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BIODEGRADABLE FLOW DIVERTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BIODEGRADABLE FLOW DIVERTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BIODEGRADABLE FLOW DIVERTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PERMANENT FLOW DIVERTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PERMANENT FLOW DIVERTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PERMANENT FLOW DIVERTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SOLITAIRE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SOLITAIRE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SOLITAIRE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TREVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TREVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TREVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FUSIFORM ANEURYSM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FUSIFORM ANEURYSM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FUSIFORM ANEURYSM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SACCULAR ANEURYSM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SACCULAR ANEURYSM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SACCULAR ANEURYSM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HEMORRHAGIC STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HEMORRHAGIC STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANTERIOR CIRCULATION STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANTERIOR CIRCULATION STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANTERIOR CIRCULATION STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY POSTERIOR CIRCULATION STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY POSTERIOR CIRCULATION STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY POSTERIOR CIRCULATION STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY CHEMICAL THROMBOLYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY CHEMICAL THROMBOLYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY CHEMICAL THROMBOLYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 247. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 248. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2032 (USD MILLION)
  • TABLE 249. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 250. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 251. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 252. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 253. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 254. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2032 (USD MILLION)
  • TABLE 255. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2032 (USD MILLION)
  • TABLE 257. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. G7 N